German Diabetic Center
Düsseldorf, North Rhine-Westphalia, 40225, Germany
NCT Number: NCT01479075
Insulin has a direct effect on the energy metabolism of the brain under basal conditions and has an effect on the hepatic glucose production, lipid metabolism and the secretion of various hormone. The effect of intranasal insulin on peripheral metabolism in humans supposedly is mediated by the vagus nerve.
The purpose of this study is to determine whether central insulin influences the human peripheral insulin sensitivity of liver and muscle and whether vagus nerve stimulation can mimick this effect.
Looking for future studies?
Notify Me30 year–70 year
All sexes
Interventional
Phase 4
Düsseldorf, North Rhine-Westphalia, 40225, Germany
Insulin has a direct effect on the energy metabolism of the brain under basal conditions and has an effect on the hepatic glucose production, lipid metabolism in the mouse model.
The purpose of this study is to determine whether central insulin influences the human peripheral insulin sensitivity of liver and muscle and energy metabolism. Intranasal insulin can be used in humans to deliver insulin to the brain and studies have shown that intranasal insulin might reduce food intake, lower body weight and modulate muscle glucose and adipose tissue lipid metabolism in himans. These effects are likely mediated by the vagus nerve as skeletal muscle insulin sensitization after intranasal insulin relates to parasympathetic tone activity (Heni et al. Diabetes 2014). Transcutaneous auricular vagus nerve stimulation (taVNS) activates non-invasively the sensory branches of the vagus nerve and is applied in humans as adjuvant treatment in drug-resistant epilepsy (Frangos et al. 2015). Thereby it can be used to examine whether the vagus nerve indeed mediates brain insulin signals to the periphery.
Here we aim to investigate the effects of intranasal insulin on hepatic glucose, lipid and energy metabolism. We further aim to test whether taVNS can mimick intranasal insulin effects on peripheral metabolism in humans.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
4x 40mU intranasal insulin
Other names: intranasal insulin
Other names: intranasal placebo spray
Other names: transcutaneous auricular vagus nerve stimulation
Other names: sham stimulation in the ear lobe
Time frame: 6 months
Assessment of insulin sensitivity with gold standard methods
Time frame: 6 months
Energy metabolism is assessed from gold standard methods
German Diabetes Center
Other
Acronym: Centrin
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01809288
Behavior, Body Weight
Bethesda, Maryland, United States
View Trial DetailsNCT06268990
Body Weight, Diabetes
Graz, Austria
View Trial DetailsNCT03514108
Cardiovascular Diseases, Diabetes
Holbæk, Region Sjælland, Denmark
View Trial DetailsNCT06697977
Body Weight, Diabetes
Amman, Jordan
View Trial Details